Kevin McCulloch - 12 Mar 2026 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Reporting relationship: President and Chief Operating Officer
Issuer ticker: XERS
Reported as of: 12 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Mar 2026, 18:11:35 UTC
Prior SEC filing: 02 Feb 2026
Next SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Beth Hecht, Attorney-in-Fact

Key filing fact

Kevin McCulloch filed Form 4 for Xeris Biopharma Holdings, Inc. (XERS) on 16 Mar 2026.

Key facts

This page summarizes Kevin McCulloch's Form 4 filing for Xeris Biopharma Holdings, Inc. (XERS).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 16 Mar 2026, 18:11.

Change

Previous filing in this sequence was filed on 02 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002031695 Primary reporting owner

McCulloch Kevin

Relationship: President and Chief Operating Officer
Address: C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO
Signature: /s/ Beth Hecht, Attorney-in-Fact
Signature date: 16 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XERS transaction

Common Stock

Options Exercise

Transaction value
Shares: +48,894
Change %: +2.8%
Price: $4.09^*
Shares after: 1,777,721
Date: 12 Mar 2026
Ownership: Direct

XERS transaction

Common Stock

Options Exercise

Transaction value
Shares: +4
Change %: +0%
Price: $3.94^*
Shares after: 1,777,725
Date: 12 Mar 2026
Ownership: Direct

XERS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 25,000
Date: 12 Mar 2026
Ownership: By Spouse
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XERS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -48,894
Change %: -53%
Price: $4.09^*
Shares after: 43,773
Date: 12 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 48,894
Exercise price: $4.09
Footnotes: F2

XERS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -4
Change %: -0.01%
Price: $3.94^*
Shares after: 79,996
Date: 12 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4
Exercise price: $3.94
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Footnote F2

The reporting person received the stock options on December 10, 2020 pursuant to an award under the Company's 2018 Stock Option/Stock Issuance Plan (the "2018 Plan"). 50% of the options vested on the first anniversary of the vesting commencement date, and the remaining 50% of options vested on the second anniversary of the vesting commencement date, in each case subject to continued employment through such vesting date.

Footnote F3

The reporting person received the stock options on August 26, 2020 pursuant to an award under the 2018 Plan. 50% of the options vested on the first anniversary of the vesting commencement date, 25% of the options vested on the 18-month anniversary of the vesting commencement date, and the remaining 25% of options vested on the two-year anniversary of the vesting commencement date, in each case subject to continued employment through such vesting date.

SEC remarks

President and Chief Operating Officer